期刊文献+
共找到6篇文章
< 1 >
每页显示 20 50 100
Antagonizing amyloid-β/calcium-sensing receptor signaling in human astrocytes and neurons: a key to halt Alzheimer's disease progression? 被引量:6
1
作者 Ilaria Dal Prà Anna Chiarini Ubaldo Armato 《Neural Regeneration Research》 SCIE CAS CSCD 2015年第2期213-218,共6页
Astrocytes' roles in late-onset Alzheimer's disease (LOAD) promotion are important, since they survive soluble or fibrillar amyloid-β peptides (Aβs) neurotoxic effects, undergo alterations of intracellular and... Astrocytes' roles in late-onset Alzheimer's disease (LOAD) promotion are important, since they survive soluble or fibrillar amyloid-β peptides (Aβs) neurotoxic effects, undergo alterations of intracellular and intercellular Ca2+ signaling and gliotransmitters release via the Aβ/a7-nAChR (αT-nicotinic acetylcholine receptor) signaling, and overproduce/oversecrete newly synthesized Aβ42 oligomers, NO, and VEGF-A via the Aβ/CaSR (calcium-sensing receptor) signaling. Recently, it was suggested that the NMDAR (N-methyl-D-aspartate receptor) inhibitor nitromemantine would block the synapse-destroying effects of Aβ/α7-nAChR signaling. Yet, this and the progressive extracellular accrual and spreading of Aβ42 oligomers would be stopped well upstream by NPS 2143, an allosteric CaSR antagonist (calcilytic). 展开更多
关键词 Alzheimer's disease amyloid-β ASTROCYTES Ca2+ calcilytic calcium-sensing receptor nitromemantine NPS 2143 aT-nicotinic acetylcholine receptor
下载PDF
钙敏感受体拮抗剂溶钙素对小鼠骨密度和骨代谢的影响 被引量:1
2
作者 董冰子 孙晓方 +3 位作者 邓玉杰 李鹏 福本诚二 李成乾 《精准医学杂志》 2019年第2期139-142,共4页
目的探讨钙敏感受体(CaSR)拮抗剂溶钙素对骨密度和骨代谢的影响,为临床骨质疏松症的治疗提供新的思路。方法 C57BL6雌性小鼠36只,随机分为对照组(A组)、高钙高维生素D饮食组(B组)、溶钙素20mg/kg灌胃治疗组(C组)、溶钙素50mg/kg灌胃治疗... 目的探讨钙敏感受体(CaSR)拮抗剂溶钙素对骨密度和骨代谢的影响,为临床骨质疏松症的治疗提供新的思路。方法 C57BL6雌性小鼠36只,随机分为对照组(A组)、高钙高维生素D饮食组(B组)、溶钙素20mg/kg灌胃治疗组(C组)、溶钙素50mg/kg灌胃治疗组(D组)、特立帕肽(PTH(1-34))20μg/kg皮下注射组(E组),小鼠分别处理12周后,测定各组小鼠海绵骨、皮质骨、全骨骨密度及骨组织中成骨关键基因如骨钙素(Bglap2)、Runt相关转录因子(Runx2)mRNA的表达,并探讨溶钙素治疗对小鼠血、尿钙的影响。结果干预12周后,B、C、D、E组全骨骨密度与A组比较明显升高,差异均有显著性(F=39.82,P<0.05);C、D组全骨骨密度水平较B组明显升高,差异有显著性(P<0.05);而D组全骨骨密度与E组比较,差异无显著意义(P>0.05)。溶钙素可上调Bglap2、Runx2mRNA的表达,改善骨转换,C、D、E组Bglap2、Runx2mRNA表达量均较A组显著上调,差异有显著性(F=27.96、21.75,P<0.05)。此外,与钙和维生素D补充和外源性PTH治疗干预组相比,溶钙素对血钙波动的影响较小,差异无显著性(P>0.05)。溶钙素也可减少尿钙排泄,D组尿钙水平较B、E组显著降低(F=2.68,P<0.05)。结论溶钙素可促进骨形成、增加骨密度,有可能成为骨质疏松症有效的治疗药物。 展开更多
关键词 溶钙素 受体 钙敏感 骨生成 骨密度 甲状旁腺素 小鼠 近交C57BL
下载PDF
Calcium-sensing receptor in colorectal inflammation and cancer:Current insights and future perspectives 被引量:10
3
作者 Luca Iamartino Taha Elajnaf +1 位作者 Eniko Kallay Martin Schepelmann 《World Journal of Gastroenterology》 SCIE CAS 2018年第36期4119-4131,共13页
The extracellular calcium-sensing receptor(CaSR) is best known for its action in the parathyroid gland and kidneys where it controls body calcium homeostasis. However, the CaSR has different roles in the gastrointesti... The extracellular calcium-sensing receptor(CaSR) is best known for its action in the parathyroid gland and kidneys where it controls body calcium homeostasis. However, the CaSR has different roles in the gastrointestinal tract, where it is ubiquitously expressed. In the colon, the CaSR is involved in controlling multiple mechanisms, including fluid transport, inflammation, cell proliferation and differentiation. Although the expression pattern and functions of the CaSR in the colonic microenvironment are far from being completely understood, evidence has been accumulating that the Ca SR might play a protective role against both colonic inflammation and colorectal cancer. For example, CaSR agonists such as dipeptides have been suggested to reduce colonic inflammation, while dietary calcium was shown to reduce the risk of colorectal cancer. CaSR expression is lost in colonic malignancies, indicating that the CaSR is a biomarker for colonic cancer progression. This dual anti-inflammatory and anti-tumourigenic role of the CaSR makes it especially interesting in colitisassociated colorectal cancer. In this review, we describe the clinical and experimental evidence for the role of the CaSR in colonic inflammation and colorectal cancer, the intracellular signalling pathways which are putatively involved in these actions, and the possibilities to exploit these actions of the CaSR for future therapies of colonic inflammation and cancer. 展开更多
关键词 Calcium-sensing receptor COLON CANCER INFLAMMATION Calcimimetics calcilytics
下载PDF
抑钙剂NPS 2143对创伤失血性休克大鼠心血管功能的影响 被引量:4
4
作者 雷艳 彭小勇 +2 位作者 李涛 刘良明 杨光明 《局解手术学杂志》 2018年第6期387-390,共4页
目的观察抑钙剂NPS 2143对创伤失血性休克(THS)大鼠心血管功能的影响。方法采用大鼠创伤失血性休克模型,观察NPS 2143输注对THS大鼠的存活情况、平均动脉血压与去甲肾上腺素诱导的升压反应、以及血流动力学指标的影响。结果未经治疗的... 目的观察抑钙剂NPS 2143对创伤失血性休克(THS)大鼠心血管功能的影响。方法采用大鼠创伤失血性休克模型,观察NPS 2143输注对THS大鼠的存活情况、平均动脉血压与去甲肾上腺素诱导的升压反应、以及血流动力学指标的影响。结果未经治疗的大鼠在创伤失血性休克后数小时内全部死亡,单纯给予乳酸林格氏液(LR)复苏有轻度的改善作用,NPS 2143输注可明显延长THS大鼠的存活时间,提高24 h存活率。休克后大鼠的血压和去甲肾上腺素(NE)诱导的升压反应都显著降低,LR复苏有一定的恢复作用,NPS 2143能明显改善血压和升压反应。同时,NPS 2143可明显改善休克后降低的血流动力学指标,如左心室收缩压(LVSP)和左心室压力最大上升/下降速率(±dp/dt_(max)),其效果明显优于单纯LR复苏。结论抑钙剂NPS 2143对创伤失血性休克后心血管功能有明显的改善作用。 展开更多
关键词 创伤失血性休克 钙敏感受体 抑钙剂 NPS 2143
下载PDF
钙敏感受体激活性和失活性突变所致骨矿代谢异常疾病及治疗 被引量:1
5
作者 董冰子 李成乾 孙晓方 《中华骨质疏松和骨矿盐疾病杂志》 CSCD 北大核心 2021年第1期66-74,共9页
钙敏感受体(calcium-sensing receptor,CaSR)是感知细胞外钙离子浓度,调节甲状旁腺素分泌及尿钙重吸收,维持钙稳态的关键受体。CaSR激活性和失活性突变导致钙调定点的移动,引起相应的钙矿物质代谢异常疾病和骨代谢异常表现。本文综述CaS... 钙敏感受体(calcium-sensing receptor,CaSR)是感知细胞外钙离子浓度,调节甲状旁腺素分泌及尿钙重吸收,维持钙稳态的关键受体。CaSR激活性和失活性突变导致钙调定点的移动,引起相应的钙矿物质代谢异常疾病和骨代谢异常表现。本文综述CaSR突变所致疾病的发病机制、临床表现、治疗策略,通过动物实验模型阐述CaSR的病理生理功能,并探讨针对上述疾病的治疗及CaSR配体药物的研究进展。 展开更多
关键词 钙敏感受体 家族遗传性低尿钙性高钙血症 常染色体显性遗传性低钙血症 溶钙素 拟钙剂
下载PDF
钙敏感受体拮抗剂(溶钙素)的临床应用
6
作者 陈盈宇 王鸥 邢小平 《中华骨质疏松和骨矿盐疾病杂志》 CSCD 北大核心 2021年第5期553-559,共7页
钙敏感受体(calcium-sensing receptor,CaSR)在人体钙稳态调控中起关键作用,溶钙素能够别构抑制CaSR。研究表明已有的溶钙素可能并非治疗骨质疏松症的有效药物,但却为CaSR及其细胞内偶联蛋白的激活突变所致疾病提供了靶向治疗的可能。... 钙敏感受体(calcium-sensing receptor,CaSR)在人体钙稳态调控中起关键作用,溶钙素能够别构抑制CaSR。研究表明已有的溶钙素可能并非治疗骨质疏松症的有效药物,但却为CaSR及其细胞内偶联蛋白的激活突变所致疾病提供了靶向治疗的可能。最近研究显示溶钙素还可能对哮喘、特发性肺动脉高压、骨关节炎、阿尔茨海默病、钙化性主动脉瓣膜病及肿瘤等疾病有一定疗效。本文就溶钙素作用机制及治疗研究进展进行综述。 展开更多
关键词 溶钙素 钙敏感受体 低钙血症 甲状旁腺功能减退 临床应用
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部